IL176603A0 - Targeted immunogens - Google Patents

Targeted immunogens

Info

Publication number
IL176603A0
IL176603A0 IL176603A IL17660306A IL176603A0 IL 176603 A0 IL176603 A0 IL 176603A0 IL 176603 A IL176603 A IL 176603A IL 17660306 A IL17660306 A IL 17660306A IL 176603 A0 IL176603 A0 IL 176603A0
Authority
IL
Israel
Prior art keywords
targeted immunogens
immunogens
targeted
Prior art date
Application number
IL176603A
Other languages
English (en)
Original Assignee
Sanofi Pasteur Inc
Uger Robert A
Salha Danielle
Gallichan Scott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc, Uger Robert A, Salha Danielle, Gallichan Scott filed Critical Sanofi Pasteur Inc
Publication of IL176603A0 publication Critical patent/IL176603A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL176603A 2003-12-31 2006-06-28 Targeted immunogens IL176603A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53372803P 2003-12-31 2003-12-31
PCT/US2004/044023 WO2005066203A2 (en) 2003-12-31 2004-12-30 Targeted immunogens

Publications (1)

Publication Number Publication Date
IL176603A0 true IL176603A0 (en) 2006-10-31

Family

ID=34748948

Family Applications (1)

Application Number Title Priority Date Filing Date
IL176603A IL176603A0 (en) 2003-12-31 2006-06-28 Targeted immunogens

Country Status (12)

Country Link
US (1) US20060002946A1 (enExample)
EP (1) EP1699492A2 (enExample)
JP (1) JP2007536911A (enExample)
KR (1) KR20060129353A (enExample)
CN (1) CN1921889A (enExample)
AU (1) AU2004312548A1 (enExample)
BR (1) BRPI0418273A (enExample)
CA (1) CA2552251A1 (enExample)
IL (1) IL176603A0 (enExample)
MX (1) MXPA06007574A (enExample)
WO (1) WO2005066203A2 (enExample)
ZA (1) ZA200605304B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103110D0 (en) * 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
KR20170116039A (ko) * 2015-02-18 2017-10-18 에프. 호프만-라 로슈 아게 표적 세포에 대항하여 t 세포 세포독성을 특이적으로 유도하기 위한 면역컨주게이트
CA2984629C (en) 2015-05-07 2024-06-18 University Of South Florida Modified ube3a gene for a gene therapy approach for angelman syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE391791T1 (de) * 2000-08-25 2008-04-15 Aventis Pharma Inc Membran penetrierende peptide und deren anwendungen
CA2477429A1 (en) * 2002-01-29 2003-08-07 Robert A. Uger Targeted immunogens

Also Published As

Publication number Publication date
WO2005066203A2 (en) 2005-07-21
US20060002946A1 (en) 2006-01-05
CN1921889A (zh) 2007-02-28
WO2005066203A3 (en) 2005-09-01
JP2007536911A (ja) 2007-12-20
BRPI0418273A (pt) 2007-05-02
EP1699492A2 (en) 2006-09-13
MXPA06007574A (es) 2007-04-17
KR20060129353A (ko) 2006-12-15
AU2004312548A1 (en) 2005-07-21
CA2552251A1 (en) 2005-07-21
ZA200605304B (en) 2007-12-27

Similar Documents

Publication Publication Date Title
EP1615948A4 (en) IMMUNOLOGICAL AMPLIFICATION
EP1635758A4 (en) ORTHODYNAMIC REEDUCATION DEVICE
DE502004011703D1 (en) N-heterocyclyl-phenylsubstituierte cyclische ketoenole
DE602004012071D1 (en) T-hilfe
EP1633834A4 (en) Improved food-grade-lubricant
DE602004020356D1 (en) Phenoxyessigsäurederivate
DE602004030538D1 (en) Präzisionssubstratlagerbehälter
EP1629178A4 (en) ANCHOR BOLT
DE502004009243D1 (en) Spirocyclische cyclohexan-derivate
DE602004027010D1 (en) Thermotherapiehülle
DE502004006683D1 (en) Injection-locked-oscillator-schaltkreis
DE502004011852D1 (en) Nspritzventil
DE60333037D1 (en) Laser-radar
DE112004002769D2 (en) Schienengeführtes transportsystem
DE502004004146D1 (en) Pyrazolverbindungen
DK1665437T3 (en) Reformeringsmodul
DE502004011343D1 (en) Rotorspinnmaschine
ZA200603778B (en) Novel oxy-nitriles
DE602004020525D1 (en) Imidazolderivate
DE502004012153D1 (en) Rotorspinnmaschine
DE10394343D2 (en) Berührungslose biometrische erkennung
DE602004009041D1 (en) Hydroxytetrahydronaphthalenylharnstoffderivate
AU155419S (en) Trivette
DE602004008281D1 (en) Avermectin-b1-monosaccharidderivative
EP1698434A4 (en) SANDERS